Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for TRN-257, a controlled-release, low-sodium oxybate product, for the treatment of c ...

With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important ...

TORONTO — Health Canada has approved the first drug designed to treat postpartum depression. Zuranolone, sold under the brand ...

ARE you struggling to turn down glasses of wine at all the Christmas parties this year, despite repeatedly vowing to cut back ...

Gabapentin is an off-label treatment for fibromyalgia and may help with pain and sleep issues. Gabapentin is usually taken in doses between 900 mg and 1,800 mg daily, divided into three doses. Side ...

In Alzheimer’s disease, microglia act as a double-edged sword. They can either protect the brain or worsen the damage, depending on their activation state.

Spinal cord injuries caused by trauma such as traffic accidents or falls can lead to the permanent loss of motor and sensory functions. That is because there is a “brake” in the spinal cord, which ...

This manuscript provides convincing evidence derived from diverse state-of-the-art approaches to suggest that non-dopaminergic projection neurons in the ventral tegmental area (VTA) make local ...

Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...